Filing summary
Entity and period: The supplied filing is Caladrius Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a filing for Lisata Therapeutics, Inc. The summary below reflects the filing text provided.
Business context and reporting period
Caladrius is a development-stage biopharmaceutical company with no revenue reported for the quarter. Its pipeline included CD34+ cell therapy candidates CLBS12 for critical limb ischemia, CLBS14-CMD for coronary microvascular dysfunction, and CLBS14-NORDA for refractory angina, as well as CLBS03 for type 1 diabetes.
Financial performance and liquidity
- Revenue: None reported. Gross margin and operating margin are not meaningful from the reported results.
- Expenses and loss: Q1 2019 operating expenses were $4.592 million, versus $5.159 million in Q1 2018. Research and development expense was $2.038 million (down about 10%); general and administrative expense was $2.554 million (down about 12%). Net loss was $4.365 million, compared with $4.984 million; loss per share was $0.44 versus $0.52.
- Cash flow: Cash used in operations was $5.486 million, compared with $6.299 million a year earlier. Investing activities provided $8.741 million, primarily from net sales of marketable securities; financing activities provided $0.870 million, including $1.0 million in stock-sale proceeds. Cash and cash equivalents increased by $4.125 million to $14.424 million.
- Liquidity: Cash, cash equivalents, and marketable securities totaled approximately $38.4 million at quarter-end; working capital was approximately $34.5 million. The company said cash on hand was expected to fund operating expenses for at least 12 months following issuance of the statements.
- Balance sheet and obligations: Total assets were $41.288 million, total liabilities $6.830 million, and total stockholders’ equity $34.458 million. The filing reports no interest expense for Q1 2019 and no material conventional debt balance. Operating lease liabilities were $1.264 million; the current portion of CIRM funding recorded in accrued liabilities was $2.583 million.
Material changes versus the prior comparable period
- Operating expenses declined 11%, and net loss narrowed by approximately $0.6 million year over year.
- Operating cash use improved by approximately $0.8 million. Investing cash flow shifted from $1.189 million used in Q1 2018 to $8.741 million provided in Q1 2019, largely reflecting marketable-security purchases and sales rather than operating performance.
- In March 2019, the company entered a stock purchase agreement with Lincoln Park, received $1.0 million for 250,000 shares, and issued 181,510 commitment shares. The agreement permits up to $26 million of additional stock sales over 36 months, subject to conditions and limits.
- Adoption of the new lease accounting standard resulted in recognition of lease assets and liabilities; the company described the adoption as noncash and not material to its financial statements.
Outlook, commentary, and risks
- Management planned to use existing cash and potentially raise capital through equity or debt, partnerships, collaborations, grants, or asset sales. It cautioned that additional financing may not be available on acceptable terms and that equity issuance may dilute shareholders.
- Management said future development of CLBS14-NORDA and any U.S. development of CLBS12 would depend on future capital raises. The company was working with the FDA to finalize the NORDA registration-trial design and targeted trial initiation in fall 2019.
- For CLBS03, February 2019 topline results showed the therapy was well tolerated, but the T-Rex study did not meet its primary endpoint of C-peptide preservation. Further development decisions awaited comprehensive data analysis.
- Management described early observations from small numbers of participants in the open-label CLBS12 and CLBS14-CMD studies as encouraging, while emphasizing that final outcomes depend on complete trial data.
- Key risks include continued operating losses, dependence on financing, clinical and regulatory uncertainty, trial enrollment and execution, and the possibility that licensing or commercialization opportunities do not produce expected value. The filing reported no material changes to previously disclosed risk factors and no pending legal matter believed likely to have a material adverse effect.
Important facts for investors to verify
- Confirm the issuer and period: the provided document identifies Caladrius Biosciences and March 31, 2019, despite the request metadata naming Lisata Therapeutics and 2018 Q1.
- Review subsequent cash use, financing activity, and the remaining availability and terms of the Lincoln Park and H.C. Wainwright equity programs.
- Check clinical-trial updates and the consequences of the failed CLBS03 primary endpoint, including any later development decision.
- Verify the FDA’s final CLBS14-NORDA trial requirements, expected timing, and funding plan.
- Assess potential dilution, lease and CIRM obligations, and whether the stated cash runway remains applicable in later filings.